The preferred cancer treatment is to achieve a high therapeutic effect as well as reduce side effects. In this study, we developed carrier-free nano drugs based on 5-fluorouracil (5FU) and cinnamaldehyde (CA) to meet the above goals. Two model drugs were spliced by acetal linkage and ester bond, which could self-assemble into nano drug particles (5FU–CA NPs) with a size of ∼170 nm. In vitro cell experiments showed 5FU–CA NPs were efficiently internalized by HepG2 cells. They then quickly exerted dual drug activities by the cleavage of acetal and ester bond, resulting in enhanced cell-killing efficacy and apoptosis. Synergistic mechanisms were achieved via the anti-metabolic effects mediated by 5FU–COOH and the oxidative damage induced by CA. In vivo anti-tumor evaluation further indicated that 5FU–CA NPs had higher tumor growth inhibition than 5FU–COOH/CA mixture (5FU–COOH + CA) and exhibited lower systemic toxicity under the same reducing dose of each drug. Overall, this is a successful synergistic anti-tumor attempt through rational self-assembly of drugs with different mechanisms and it can be extrapolated to other agents.
RheeYSMansourHM.Nanopharmaceuticals I: nanocarrier systems in drug delivery. IJNT2011; 8: 84–114.
2.
HanLWangTMuS, et al. Unified d-α-tocopherol 5-Fu/SAHA bioconjugates self-assemble as complex nanodrug for optimized combination therapy. Nanomedicine (Lond)2018; 13: 1285–1301.
3.
FarokhzadOCLangerR.Impact of nanotechnology on drug delivery. ACS Nano2009; 3: 16–20.
4.
CamachoKMMenegattiSVogusDR, et al. DAFODIL: a novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy. J Control Release2016; 229: 154–162.
5.
SinhaRKimGJNieS, et al. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther2006; 5: 1909–1917.
6.
HuoDJiangXHuY. Recent advances in nanostrategies capable of overcoming biological barriers for tumor management. Adv Mater 2020; 32: Article 1904337.
7.
SunQZhouZQiuN, et al. Rational design of cancer nanomedicine: nanoproperty integration and synchronization. Adv Mater2017; 29: 1606628.
8.
ChoKWangXNieS, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res2008; 14: 1310–1316.
9.
WangXYangCZhangY, et al. Delivery of platinum (IV) drug to subcutaneous tumor and lung metastasis using bradykinin-potentiating peptide-decorated chitosan nanoparticles. Biomaterials2014; 35: 6439–6453.
10.
YangMYZhaoRRFangYF, et al. Carrier-free nanodrug: a novel strategy of cancer diagnosis and synergistic therapy. Int J Pharm2019; 570: 118663.
11.
HanXChenJJiangM, et al. Paclitaxel-paclitaxel prodrug nanoassembly as a versatile nanoplatform for combinational cancer therapy. ACS Appl Mater Interfaces2016; 8: 33506–33513.
12.
HuangPWangDSuY, et al. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy. J Am Chem Soc2014; 136: 11748–11756.
13.
ZhangRXingRJiaoT, et al. Carrier-free, chemophotodynamic dual nanodrugs via self assembly for synergistic antitumor therapy. ACS Appl Mater Interfaces2016; 8: 13262–13269.
14.
PeiQHuXZhouJ, et al. Glutathione-responsive paclitaxel dimer nanovesicles with high drug content. Biomater Sci2017; 5: 1517–1521.
15.
LiCLinJWuP, et al. Small molecule nanodrug assembled of dual-anticancer drug conjugate for synergetic cancer metastasis therapy. Bioconjug Chem2018; 29: 3495–3502.
16.
ThomasSTomehNTheardS.Fluorouracil-induced hyperammonemia in a patient with colorectal cancer. Anticancer Res2015; 35: 6761–6763.
17.
MishraBJKaulATrivediP.L-cysteine conjugated poly l-lactide nanoparticles containing 5-fluorouracil: formulation, characterization, release and uptake by tissues in vivo. Drug Deliv2015; 22: 214–222.
18.
ZhaoDZhangHTaoW, et al. A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity. Biomater Sci2017; 5: 502–510.
19.
DaumarPDecombatCChezalJM, et al. Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs. Eur J Med Chem2011; 46: 2867–2879.
20.
KohWSYoonSYKwonB, et al. Cinnamaldehyde inhibits lymphocyte proliferation and modulates T-cell differentiation. Int J Immunopharmacol1998; 20: 643–660.
21.
ShaughnessyDTSetzerRWDeMariniDM.The antimutagenic effect of vanillin and cinnamaldehyde on spontaneous mutation in salmonella TA104 is due to a reduction in mutations at GC but not at sites. Mutat Res2001; 480: 55–69.
22.
YuCLiuSQiM, et al. Cinnamaldehyde/chemotherapeutic agent interaction and drug-metabolizing genes in colorectal cancer. Mol Med Rep2014; 9: 669–676.
23.
KangHOckJLeeH, et al. Early growth response protein 1 upregulation and nuclear translocation by 2′-benzoyloxycinnamaldehyde induces prostate cancer cell death. Cancer Lett2013; 329: 217–227.
24.
KimBLeeEKimY, et al. Dual acid-responsive micelle-forming anticancer polymers as new anticancer therapeutics. Adv Funct Mater2013; 23: 5091–5097.
25.
NohJKwonBHanE, et al. Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death. Nat Commun2015; 6: 6907.
26.
HuangTFuHHoC, et al. Induction of apoptosis by cinnamaldehyde from indigenous cinnamon cinnamomum osmophloeum kaneh through reactive oxygen species production, glutathione depletion, and caspase activation in human leukemia k562 cells. Food Chem2007; 103: 434–443.
27.
ChuangLYGuhJYChaoLK, et al. Anti-proliferative effects of cinnamaldehyde on human hepatoma cell line. Food Chem2012; 133: 1603–1610.
28.
LeeESGaoZBaeYH.Recent progress in tumor pH targeting nano-technology. J Control Release2008; 132: 164–170.
29.
LuoCSunJSunB, et al. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy. Trends Pharmacol Sci2014; 35: 556–566.
30.
BachelderEMBeaudetteTTBroadersKE, et al. Acetal derivatized dextran: an acid-responsive biodegradable material for therapeutic applications. J Am Chem Soc2008; 130: 10494–10495.
31.
YooWYooDHongE, et al. Acid-activatable oxidative stress-inducing polysaccharide nanoparticles for anticancer therapy. J Control Release2018; 269: 235–244.
32.
PanGBaoYXuJ, et al. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer. RSC Adv2016; 6: 42109–42119.
33.
UchinoJTakayamaKHaradaA, et al. Tumor targeting carboxylesterase fused with anti-CEA scFV improve the anticancer effect with a less toxic dose of irinotecan. Cancer Gene Ther2008; 15: 94–100.
34.
SunZSunBSunC, et al. A poly (glycerol-sebacate-(5-fluorouracil-1-acetic acid)) polymer with potential use for cancer therapy. J Bioact Compat Polym2012; 27: 18–30.
35.
MohankandhasamyRJin-HyungLJintaeL.Development of gold nanoparticles coated with silica containing the antibiofilm drug cinnamaldehyde and their effects on pathogenic bacteria. Int J Nanomed2017; 12: 2813–2828.
36.
BhadraDBhadraSJainSK, et al. A pegylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm2003; 257: 111–124.
37.
DanhierFAnsorenaESilvaJM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release2012; 161: 505–522.
38.
FangJSekiTMaedaH.Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev2009; 61: 290–302.
39.
FruehaufJPMeyskensFL.Reactive oxygen species: a breath of life or death?Clin Cancer Res2007; 13: 789–794.
40.
ZhenXWangXXieC, et al. Cellular uptake, antitumor response and tumor penetration of cisplatin loaded milk protein nanoparticles. Biomaterials2013; 34: 1372–1382.
41.
TorchilinVP.Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev2011; 63: 131–135.
42.
DawidczykCMKimCParkJH, et al. State-of-the art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release2014; 187: 133–144.
43.
RogerMClavreulAVenier-JulienneM, et al. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials2011; 32: 2106–2116.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
